{
    "clinical_study": {
        "@rank": "82237", 
        "arm_group": {
            "arm_group_label": "single-arm", 
            "arm_group_type": "Experimental", 
            "description": "Two capsules in the morning, one at night, every day for a month, taken with a glass of water."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the administration of the PhytoMed\u2122\n      complement reduces CRP in women with histologically confirmed AJCC Stage 0-IIIA breast\n      cancer which has been completely surgically resected and  without evidence of disease as\n      determined by their physician"
        }, 
        "brief_title": "Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed\u2122", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women with histologically confirmed AJCC Stage 0-IIIA breast cancer which has been\n             completely surgically resected.\n\n          -  No evidence of disease as determined by their physician.\n\n          -  ER+ and/or PR+ tumour.\n\n          -  Receiving an aromatase inhibitor (letrozole, anastrazole, exemestane) or tamoxifen at\n             a stable dose for at least 3 months at trial entry.\n\n          -  Post-menopausal women, defined as: (1) above 50 years of age who have not menstruated\n             during the preceding 12 months or who have follicle-stimulating hormone levels (FSH)\n             > 40 IU/L, (2) those under 50 years of age who have FSH hormone levels >40 IU/L, or\n             (3) those who have undergone a bilateral oophorectomy.\n\n          -  CRP \u22653.9 mg/L measured as the mean of two consecutive weekly tests.\n\n          -  Aged 18 years or older\n\n          -  ECOG performance status 0-1\n\n          -  Between 2 and 5 years from their initial surgery for breast cancer.\n\n          -  Life expectancy of at least 6 months\n\n          -  At least 6 months since last chemotherapy\n\n          -  Laboratory tests performed within 14 days of trial starting:\n\n               1. Granulocytes \u2265 1,500/\u00b5L;\n\n               2. Platelets \u2265 100,000/\u00b5L;\n\n               3. Haemoglobin \u2265 12.0 g/dL;\n\n               4. Total bilirubin equal to or below upper limit of normal (ULN);\n\n               5. AST and ALT equal to or below ULN;\n\n               6. Alkaline phosphatase equal to or below ULN;\n\n               7. Serum creatinine equal to or below ULN;\n\n          -  Able to provide informed consent to receive the trial treatment, to provide\n             biological specimens, self-administer oral medica-tion unsupervised for a prolonged\n             period of time, and to complete a medication diary.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breastfeeding\n\n          -  Who have had a malignancy (other than breast cancer) which required radiotherapy or\n             systemic treatment within the past 5 years.\n\n          -  Known cardiac disease (arrhythmias, myocardial infarction, bundle branch block,\n             ischemic heart disease, uncontrolled hypertension)\n\n          -  Known autoimmune disease or inflammatory disorder\n\n          -  Any condition requiring the use of systemic corticosteroids or any other\n             immunosuppressive agents (e.g. cyclosporin, tacrolimus, azathioprine).\n\n          -  Women with known immunodeficiency (such as HIV).\n\n          -  Patients with infection by septicaemia, infection, acute hepatitis, or other\n             uncontrolled severe medical condition\n\n          -  Routine use of aspirin >81 mg/d or NSAIDs (> 400 mg po 4 times/day of ibuprofen or\n             naproxen > 500 mg/d) or any use of celecoxib or similar COX-2 inhibitors;\n\n          -  Subjects are asked not to take dietary supplements, olives or olive oil for 1 month\n             prior to trial enrolment and during the trial.\n\n          -  Who are taking bisphosphonates"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819948", 
            "org_study_id": "Phytomed"
        }, 
        "intervention": {
            "arm_group_label": "single-arm", 
            "intervention_name": "PhytoMed\u2122", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Stage 0-IIIA", 
            "No evidence of disease"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "mjnoelia@hotmail.com", 
                    "last_name": "Noelia Martinez Ya\u00f1ez", 
                    "phone": "91 336 82 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }, 
                "investigator": {
                    "last_name": "Noelia Martinez Ya\u00f1ez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mprovencio.htph@salud.madrid.org", 
                    "last_name": "Mariano Provencio", 
                    "phone": "91 191 71 47"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Puerta de Hierro"
                }, 
                "investigator": {
                    "last_name": "Mariano Provencio", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zamorapilar@gmail.com", 
                    "last_name": "Pilar Zamora", 
                    "phone": "91 727 75 16"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }, 
                "investigator": {
                    "last_name": "Pilar Zamora", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ramonperezcarrion@gmail.com", 
                    "last_name": "Ram\u00f3n P\u00e9rez Carri\u00f3n", 
                    "phone": "91 452 19 87"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Quir\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Ram\u00f3n P\u00e9rez Carri\u00f3n", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "agonzalezm@seom.org", 
                    "last_name": "Antonio Gonz\u00e1lez", 
                    "phone": "91 787 86 00", 
                    "phone_ext": "2883"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Antonio Gonz\u00e1lez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Clinical Trial to Assess Changes in Biomarkers of Cancer Related to Inflammation in Women With Stage 0-IIIA Breast Cancer and Without Evidence of Disease Who Were Given the PhytoMed\u2122 Complement.", 
        "other_outcome": [
            {
                "description": "Frequency and intensity of adverse events and frequency of patients with each adverse event.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Form start of treatment to day 60"
            }, 
            {
                "description": "Frequency and intensity of treatment related adverse events and frequency of patients with each treatment related adverse event.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Form start of treatment to day 60"
            }
        ], 
        "overall_contact": {
            "email": "juanluis.sanz@apices.es", 
            "last_name": "Juan L Sanz", 
            "phone": "+34918166804", 
            "phone_ext": "103"
        }, 
        "overall_contact_backup": {
            "email": "ana.moreno@apices.es", 
            "last_name": "Ana M Moreno", 
            "phone": "918166804", 
            "phone_ext": "100"
        }, 
        "overall_official": {
            "affiliation": "Phytogen Medical Foods S.L.", 
            "last_name": "Guillermo Mu\u00f1oz", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction in serum levels of CRP from selection period to end-of-treatment", 
            "measure": "Reduction in the levels of CRP", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 33 +/- 2 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction in serum levels of IL-6 from selection period to end-of-treatment", 
                "measure": "Reduction in IL-6", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Increase in serum levels of IL-10 from selection period to end-of-treatment", 
                "measure": "Increase in the levels of IL-10", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Frequency of gastrointestinal adverse events and frequency of patients with gastrointestinal adverse events.", 
                "measure": "Safety and tolerability (Gastrointestinal symptoms)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Pain reduction from selection period to end-of-treatment", 
                "measure": "Pain intensity score measured with the BPI scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Changes in lipid profile from selection period to end-of-treatment", 
                "measure": "Effect on lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Reduction in serum levels of SAA from selection period to end-of-treatment", 
                "measure": "Reduction SAA (serum amyloid A)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Reduction in serum levels of IFN gamma from selection period to end-of-treatment", 
                "measure": "Reduction IFNgamma", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Reduction in serum levels of TNF-alpha from selection period to end-of-treatment", 
                "measure": "Reduction TNF-alpha", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Increase in serum levels of TGF beta from selection period to end-of-treatment", 
                "measure": "Increase in the levels of TGFbeta (transforming growth factor beta)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }, 
            {
                "description": "Reduction in serum levels of IGF from selection period to end-of-treatment", 
                "measure": "Reduction in IGF (insulin growth factor)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 33 +/- 2 days"
            }
        ], 
        "source": "Phytogen Medical Foods S.L.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Phytogen Medical Foods S.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}